Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-29
2005-11-29
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S254020, C514S254060, C540S575000, C544S362000, C544S369000, C544S370000
Reexamination Certificate
active
06969711
ABSTRACT:
The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same.The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof.(In the formula,is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group whereAr is an optionally substituted aryl group;X is —NH—, oxygen atom or sulfur atom;Y is —NR1—, oxygen atom, sulfur atom, sulfoxide or sulfone;Z is a single bond or —NR2—;R1is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;R2is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;l is an integer of from 0 to 15;m is an integer of 2 or 3; andn is an integer of from 0 to 3).The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).
REFERENCES:
patent: 0 372 445 (1990-06-01), None
patent: 0 807 627 (1997-11-01), None
patent: WO 92/07825 (1992-05-01), None
patent: WO 98/42680 (1998-10-01), None
patent: WO 99/25712 (1999-05-01), None
Grant, David J.W., “University of Minnesota- Twin Cities Campus College of Pharmacy, Annual Report,” 1999.
Ulrich, Joachim, “Kirk-Othmer Encyclopedia of Chemical Technology”, John Wilet & Sons, 2002.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358-365.
Brown, Michael S. et al., “Lipoprotein Metabolism In The Macrophage: Implications for Cholesterol Deposition In Atherosclerosis,” Ann. Review Biochem., 1983, vol. 52, pp. 223-261.
Ross, Russell, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, 1993, pp. 801-809.
Bocan, Thomas M.A. et al., “Comparison of CI-976, an ACAT Inhibitor, and Selected Lipid-Lowering Agents for Antiatherosclerotic Activity in lliac-Femoral and Thoracic Aortic Lesions,” Arteriosclerosis and Thrombosis, vol. 11, No. 6, 1991, pp. 1830-1843.
O'Brien, Patrick M. et al., “ACAT Inhibitors: A Potential New Approach to the Treatment of Hypercholesterolaemia and Atherosclerosis,” Therapeutic Patents, vol. 2, No. 4, 1992, pp. 507-526.
Iiskovic Dargo R., “ACAT Inhibitor: Potential Anti-atherosclerotic Agents,” Current Medicinal Chemistry, 1994, pp. 204-225.
Scandinavian Simvastatin Survival Group, “Randomizes trial of cholesterol lowering in 4444 patient with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),” The Lancet, vol. 344, 1994, pp. 1383-1389.
Edano Toshiyuki
Hirata Mitsuteru
Kawamine Katsumi
Miura Toru
Ohgiya Tadaaki
Alexander John B.
Corless Peter F.
Edwards & Angell LLP
Kowa Company Ltd.
McKenzie Thomas C.
LandOfFree
Cyclic diamine compounds and medicine containing the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic diamine compounds and medicine containing the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic diamine compounds and medicine containing the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468267